Short communication

, Volume: 12( 2) DOI: -

• View PDF
• Download PDF

Discovery and Development to Reverse Resistance to our Antibiotics Currently used

*Correspondence:

Ben Marten Department of Antibiotics, Ferric University, Germany, E-mail: evelyn@8967gmail.com

Abstract

  

Introduction

Antibiotic resistance develops as a result of medications that only target specific bacterial compounds almost always proteins. Furthermore, there is growing worry about antibiotic misuse in livestock production, which Staphylococcus aurous, vancomycin-resistant enterococci and macrolide-resistant Streptococcus are examples of accounts for three times the amount of antibiotics given to humans in the European Union alone, contributing to the creation of super-resistant bacteria[1]. Bacteria can not only change the enzyme that antibiotics target, but they can also utilise enzymes to modify the antibiotic itself, neutralising it. Target-altering pathogens, whereas Pseudomonas aeruginosa and aminoglycoside-resistant Acinetobacter baumannii are examples of antibiotic-modifying bacteria. Resistance to drugs, toxins, or chemicals is a result of evolution and a response to forces exerted on every living creature. Individual organisms differ in their sensitivity to the drug, and those with higher fitness may be able to withstand drug treatment. Drug-resistant features are passed down over the generations, resulting in a population that is more drug-resistant.

Description

Resistance to the drug will almost certainly develop unless the drug used prevents sexual reproduction, cell division, or horizontal gene transfer in the whole target population. This is evident in malignant tumours, as certain cells gain resistance to chemotherapeutic medicines [2]. Chemotherapy causes huge levels of the protein WNT16B to be produced in fibroblasts around tumours. This protein promotes cancer cell proliferation in drug-resistant cancer cells. MicroRNAs have also been demonstrated to influence acquired drug resistance in cancer cells, which could be employed therapeutically. Malaria has resurfaced as a hazard in Southeast Asia and Sub-Saharan Africa in 2012, with drug-resistant Plasmodium falciparum genotypes providing significant challenges for health officials [3]. Dapsone resistance is growing in leprosy. We created a method for estimating the burden of AMR that incorporates all available data and builds on death and incidence estimates for various underlying conditions from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, which provides age- and sex-specific estimates of disease burden for 369 diseases and injuries in 204 countries and territories from 1990 to 2019.

Our method may be broken down into ten estimation steps that take place within five main modeling components. To begin, we gathered data from a variety of sources, including published studies e.g., microbiology data, inpatient data, data on multiple causes of death, and pharmaceutical sales data as well as direct sources such as collaborators on the Global Research on Antimicrobial Resistance project, members of the GBD Collaborator Network, and other data providers[4]. For 12 main infectious syndromes, we calculated the illness loads linked to and attributable to AMR. Lower respiratory infections, including thorax infections; bloodstream infections; peritoneal and intra-abdominal infections; meningitis and other bacterial CNS infections; typhoid, paratyphoid, and invasive non-typhoidal Salmonella spp; urinary tract infections and pyelonephritis; diarrhoea; tuberculosis bacterial infections of the skin and subcutaneous systems endocardit.. There are 88 pathogen–drug combinations, as well as 18 drug categories or combinations of medications for which there is resistance. For 204 countries and territories, we modelled all-age and age-specific fatalities and disability-adjusted life-years, and we give aggregated estimates for 21 GBD regions, seven GBD super-regions, and globally in 2019.

Conclusion

Drug resistance is the primary cause of malignant tumour treatment failure. Drug resistance exists in 50 percent of instances even before chemotherapy begins. Increased protein expression leading to drug removal, mutation of drug-binding sites, restoration of tumour protein production, and the presence of genetically diverse tumour cell populations are only a few of the anticancer drug resistance mechanisms that have been discovered. Secondary mutations in BRCA1/2 proteins that restore their activity, for example, have been identified as a crucial mechanism for conferring tumour resistance. This restoration is frequently a side effect of cisplatin or polymerase inhibitor therapy; both drugs can create resistance not only to their own use, but also to the other therapeutic technique.

Acknowledgment

The authors are grateful to the journal editor and the anonymous reviewers for their helpful comments and suggestions.

Declaration for Conflicts of Interests

The authors declared no potential conflicts of interest for the research, authorship, and/or publication of this article.

References

1. Martinez JL. General principles of antibiotic resistance in bacteria. Drug Discov Today Technol. 2014;11: 33-39 

   [Cross Ref][Google Scholar][PubMed]

2. Wencewicz AT. Crossroads of Antibiotic Resistance and Biosynthesis. Microbiol Mol Biol. 2019; 74(3)

   [Cross Ref][Google Scholar][PubMed]

3. Munita JM. Mechanisms of Antibiotic Resistance Microbiol Spectr. 2016;4(2)

   [Cross Ref][Google Scholar][PubMed]

4. Ghosh D. Antibiotic Resistance and Epigenetics: More to It than Meets the Eye. Antimicrob Agents Chemother. 2020; 64(2).

   [Cross Ref][Google Scholar][PubMed]